Alector (ALEC) FY 2025 earnings snapshot

Alector (ALEC) has just closed out FY 2025 with Q4 revenue of about US$6.2 million and a basic EPS loss of roughly US$0.34. On a trailing twelve month basis, revenue stood at around US$21.0 million and EPS at a loss of about US$1.39. Over recent quarters the company has reported quarterly revenue ranging from roughly US$3.3 million to US$7.9 million in 2025, with basic EPS losses between about US$0.30 and US$0.41. This points to a profile where revenue remains modest while earnings are still firmly in negative territory, so investors are likely to focus on how margins and cost discipline evolve from here.

See our full analysis for Alector.

With the headline numbers on the table, the next step is to see how this earnings profile aligns with the widely held narratives about Alector's growth potential, risk profile, and long term margin story.

TTM loss of US$142.9 million keeps profitability distant

• Over the trailing twelve months, Alector reported total revenue of about US$21.0 million against a net loss of roughly US$142.9 million, and basic EPS over that period was a loss of about US$1.39.
• Consensus narrative points to late stage programs like latozinemab as potential future revenue drivers. However, the current figures show earnings power is still heavily negative, with TTM losses of around US$142.9 million even as revenue is reported at about US$21.0 million.
  • This setup fits the consensus view that high R&D spend is necessary to progress the neurodegeneration pipeline. It also matches the data showing Alector remains unprofitable, with losses having grown at about 1.8% per year over five years.
  • At the same time, the relatively modest 8.5% revenue growth rate over the last year compared with an 11.4% US market growth rate indicates that the pipeline claims are not yet reflected in faster top line expansion in the reported financials.

Premium 12.9x P/S against peers despite losses

• Alector trades on a P/S of 12.9x compared with a peer average of 6.7x and a US biotech industry average of 10.9x, while the company is still loss making with TTM net income of about US$142.9 million in the red.
• Bulls argue that late stage assets and the ABC platform could justify a richer valuation, yet the current numbers highlight a tension between that optimistic story and what is on the income statement.
  • The consensus narrative points to potential upside if pivotal trials succeed. Today, the stock sits at around US$2.44 with no profitability and a revenue base of roughly US$21.0 million on the latest TTM numbers.
  • Against an allowed analyst price target of US$3.10, the premium P/S multiple alongside ongoing losses suggests that any bullish case is leaning heavily on future trial outcomes rather than current financial performance.

On these numbers, bulls are effectively betting that current heavy losses will translate into future outcomes that justify paying a premium multiple today, so it helps to see how that thesis is laid out in detail in the 🐂 Alector Bull Case.

Insider selling and ongoing loss trend back the bears

• Insiders have been significant net sellers over the past three months, at a time when Alector remains unprofitable and losses have grown by about 1.8% per year over the last five years, with forecasts indicating the business is expected to stay loss making for at least the next three years.
• Bears highlight the combination of a small FTD GRN market, high R&D spend and continued losses as a key concern, and the recent data gives them several concrete points to lean on.
  • On the income statement, FY 2025 quarterly net losses range from roughly US$30.5 million to US$40.5 million, while TTM net loss is about US$142.9 million. This aligns with the bearish view that cash burn remains substantial.
  • With insiders selling and no forecast path to profitability over the coming three years in the provided data, the cautious narrative that dilution or funding needs could stay in focus is firmly grounded in the current financial profile rather than sentiment alone.

If you are weighing that cautious stance, it is worth seeing exactly how skeptics frame the trade off between clinical potential and ongoing losses in the 🐻 Alector Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alector on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of bullish potential and clear risks feels finely balanced, now is the time to look closely at the details yourself and decide how comfortable you are with the trade off. You can begin by reviewing the 2 important warning signs.

See What Else Is Out There

Alector is still reporting sizeable losses of about US$142.9 million on modest revenue of roughly US$21.0 million, with insider selling adding to the caution.

If you want stocks where the price tag lines up more closely with current fundamentals, check out the 51 high quality undervalued stocks to spot ideas that may offer better value today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.